Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Research from Technical University of Dresden has provided new data on bladder cancer
October 21st, 2008
According to recent research from Dresden, Germany, "The knockdown of XIAP, BCL2 and BCL-X-L by siRNAs represents a promising treatment option for bladder cancer (BCa) since the overexpression of antiapoptotic genes is often associated with tumor progression and treatment resistance. EJ28 BCa cells were transfected with siRNAs - separately and combined-followed by analysis of target expression, viability, clonogenic survival, apoptosis and cell cycle." "Furthermore, a possible chemosensitization by siRNA pretreatment was investigated. The siRNA-mediated inhibition of these targets - either separately or combined-reduced the targets' expression, reduced cell growth and...
Source: Cancer Weekly (2008-10-21)
|
